ImmunityBio Inc. (NASDAQ:IBRX) shares are up on Thursday as the company reported a significant increase in net product revenue, showcasing strong growth in its commercial operations.

The positive momentum follows the announcement that multiple regulatory jurisdictions have approved Anktiva, reflecting growing physician adoption and disciplined commercial execution, which have driven the stock upward, increasing nearly 2.7 times year-over-year.

Q1 Revenue Jumps

ImmunityBio reported preliminary net product revenue of approximately $44.2 million for the first quarter of 2026, marking a 168% increase compared to the same quarter last year.

The company ended the quarter with an estimated $380.9 million in cash and equivalents, positioning it well for future growth.

Anktiva is now approved or authorized across five regulatory jurisdictions, representing approximately 34 countries.

Additionally, the pivotal BCG-naïve CIS trial (QUILT-2.005) is fully enrolled, with ...